CD274 and hepatocellular carcinoma: More recently, the combination of the anti-PD-L1 antibody durvalumab with the anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) antibody tremelimumab has become available for similar patient profiles [7], further expanding the therapeutic options and underscoring the critical role of combination therapies in managing advanced HCC [2,3,4,5,6,7].